UMediC Group Bhd (UMC) exceeded expectations for its FY25 earnings, with core profits of RM8.2 million surpassing forecasts by 113–126%, according to Hong Leong Investment Bank (HLIB). The company’s respiratory product segment is poised for growth, supported by global healthcare trends like an ageing population. However, HLIB noted that uncertainties in UMC’s distribution division may dampen overall momentum. Despite a 15.4% year-on-year earnings dip, UMC’s strong fourth-quarter performance up 60% quarter-on-quarter prompted an upward revision in its target price, reinforcing confidence in the company’s manufacturing-led future.
